Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 227 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Genetic Expression Clear all

Conditions: Head and Neck Cancer
Interventions: Southern blotting, TdT-mediated dUTP nick end labeling assay, gene expression analysis, protein expression analysis, flow cytometry, fluorescent antibody technique, immunoenzyme technique, immunohistochemistry staining method, immunologic technique; Genetic · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Leukemia
Interventions: DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 16 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Genetic Polymorphism
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions: Corus CAD (ASGES); Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 4,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: Anchorage, Alaska • Beverly Hills, California • La Jolla, California + 7 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Beclomethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions: Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy; Other · Genetic · Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Microarray analysis, Laboratory biomarker analysis; Genetic · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Lymphoma
Interventions: DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Food Allergy in Children
Interventions: Skin tape stripping, Skin barrier assessment, Blood draw; Diagnostic Test · Device
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Autism Spectrum Disorder
Interventions: KF-STRIDE®; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 14 Years to 26 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic, Hepatitis, Viral, Human
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 1,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Childhood Hepatoblastoma, Stage I Childhood Liver Cancer, Stage II Childhood Liver Cancer, Stage III Childhood Liver Cancer, Stage IV Childhood Liver Cancer
Interventions: RNA analysis, gene expression analysis, microarray analysis, nucleic acid sequencing, diagnostic laboratory biomarker analysis; Genetic · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 16 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Colorectal Cancer
Interventions: celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery; Drug · Genetic · Other + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: Prolaris; Behavioral
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: San Diego, California • West Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Refractory Multiple Myeloma
Interventions: pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 3,087 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET); Biological · Drug · Genetic + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Atrial Fibrillation
Interventions: Atrial biopsy; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-Related Osteoporosis
Interventions: Sample collection for gene expression; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Interventions: PM359; Biological
Lead sponsor: Prime Medicine, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee

Search by objective public record fields.

Study of Proteins in Head and Neck Cancer Cells

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications

Genetic Study of Age-Related Macular Degeneration

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

Effect of Steroids on Gene Expression in the Healthy Smokers Lungs

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Skin Characteristics of Parents of Food Allergic Pediatric Patients

A Strength-Based Intervention to Improve Job Interview Skills in Young Adults in a Community Setting

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

Biomarkers in Tissue Samples From Young Patients With Liver Cancer

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Prospective Prolaris Value and Efficacy

Genetic and Protein Profiling in Normal and Cancerous Breast Tissue

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Blood Collection From Individuals With Lung Disease for Genetic Studies

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Genomics of Kidney Transplantation

Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )